NCT00181636 is a NA clinical trial of Galantamine-CR in Bipolar Disorder, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT00181636?

NCT00181636 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT00181636?

Interventions in NCT00181636: Galantamine-CR.

What condition does NCT00181636 study?

NCT00181636 studies Bipolar Disorder.

Is NCT00181636 still recruiting?

NCT00181636 is currently completed. Last updated 23 April 2007.

Last reviewed 2007-04-23 · How we verify

NCT00181636

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder

Completed NA Last updated 23 April 2007

What this trial tests

NA trial testing Galantamine-CR in Bipolar Disorder in 25 participants. Completed in 1 October 2006.

Timeline

1 October 2006

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Estimated completion	1 October 2006
Sites	1 location across United States

Drugs / interventions tested

Galantamine-CR — full drug profile →

Conditions studied

Bipolar Disorder — all drugs for Bipolar Disorder →

Sponsor

Massachusetts General Hospital

Who can join

Adults 18 to 65, any sex, with Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

neurocognitive testing at last study visit (18 weeks)

Sponsor's own description

The purpose of the study is to determine whether the investigational drug galantamine-CR (Reminyl- Controlled Release capsule) is useful in improving problems with memory in bipolar patients with stable mood. This study is being done because a large proportion of patients with bipolar disorder experience significant memory problems, even when their mood is stable, after adequate treatment. These memory problems have been associated with poor daily social functioning. Studying galantamine-CR in this population may provide a new clinical way to combat memory problems in stable patients with bipolar disorder.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study.
Iosifescu DV, Moore CM, Deckersbach T, Tilley CA, et al · · 2009 · cited 32× · PMID 19889129 · DOI 10.1111/j.1755-5949.2009.00090.x

Verify or expand the search:

Other recruiting trials for Bipolar Disorder

Currently open trials in the same condition.

NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT06911931 — Visual Perception in Schizophrenia · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07479758 — Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Out · recruiting
NCT07140913 — A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Featur · Phase 3 · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00181636 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 23 April 2007

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00181636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing